The Prevention of Delirium and Complications Associated with Surgical Treatments (PODCAST) study: protocol for an international multicentre randomised controlled trial

Citation

Published Version
doi:10.1136/bmjopen-2014-005651

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12987336

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
ABSTRACT

Introduction: Postoperative delirium is one of the most common complications of major surgery, affecting 10–70% of surgical patients 60 years and older. Delirium is an acute change in cognition that manifests as poor attention and illogical thinking and is associated with longer intensive care unit (ICU) and hospital stay, long-lasting cognitive deterioration and increased mortality. Ketamine has been used as an anaesthetic drug for over 50 years and has an established safety record. Recent research suggests that, in addition to preventing acute postoperative pain, a subanaesthetic dose of intraoperative ketamine could decrease the incidence of postoperative delirium as well as other neurological and psychiatric outcomes. However, these proposed benefits of ketamine have not been tested in a large clinical trial.

Methods: The Prevention of Delirium and Complications Associated with Surgical Treatments (PODCAST) study is an international, multicentre, randomised controlled trial. 600 cardiac and major non-cardiac surgery patients will be randomised to receive ketamine (0.5 or 1 mg/kg) or placebo following anaesthetic induction and prior to surgical incision. For the primary outcome, blinded observers will assess delirium on the day of surgery (postoperative day 0) and twice daily from postoperative days 1–3 using the Confusion Assessment Method or the Confusion Assessment Method for the ICU. For the secondary outcomes, blinded observers will estimate pain using the Behavioral Pain Scale (BPS) and the Behavioral Pain Scale—Non-Intubated (BPS-NI). Delirium is fluctuating in nature. Since patients will be assessed at discrete time points, it is possible that some episodes of delirium will not be detected.

Ethics and dissemination: The PODCAST trial has been approved by the ethics boards of five participating institutions; approval is ongoing at other sites. Recruitment began in February 2014 and will continue until the end of 2016. Dissemination plans include presentations at scientific conferences, scientific publications, stakeholder engagement and popular media. Registration details: The study is registered at clinicaltrials.gov, NCT01690988 (last updated March 2014). The PODCAST trial is being conducted under the auspices of the Neurological Outcomes Network for Surgery (NEURONS).

Trial registration number: NCT01690988 (last updated December 2013).

INTRODUCTION

Background and rationale

Delirium

Postoperative delirium is one of the most common complications of major surgery and affects between 10% and 70% of all surgical

Strengths and limitations of this study

- Since the Prevention of Delirium and Complications Associated with Surgical Treatments (PODCAST) study is a multicentre international trial, the results of the study will potentially be generalisable.
- This trial has a novel focus of assessing delirium and pain concurrently. Results could reveal that these two outcomes are potentially linked in the postoperative setting.
- Investigators assessing for delirium have been appropriately trained and will use reliable and validated assessment tools.
- The Visual Analog Scale (VAS) is not a validated pain assessment instrument in delirious patients. In an attempt to mitigate this limitation, pain will also be assessed observationally using the Behavioral Pain Scale (BPS) and the Behavioral Pain Scale—Non-Intubated (BPS-NI).
- Delirium is fluctuating in nature. Since patients will be assessed at discrete time points, it is possible that some episodes of delirium will not be detected.
patients older than 60 years (table 1). The estimated additional healthcare costs associated with delirium exceed $60 000 per patient per year. While causal relationships have not been established, delirium is associated with increased morbidity and mortality, prolonged length of hospital and intensive care unit (ICU) stay, functional and cognitive decline with nursing home or long-term care facility placement. Furthermore, the acute deterioration in cognition and psychomotor agitation frequently seen with delirium is often distressing for both patients and their families.

The diagnostic criteria for delirium have recently been updated in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V). Delirium is an acute neurocognitive disorder characterised by a fluctuating level of consciousness with impairment of attention and cognition. In the postoperative context, delirium typically manifests between 0 and 96 h following surgical intervention. It is unclear why postoperative delirium occurs so frequently. Age greater than 60, male gender, history of dementia or depression, sensory impairment and chronic medical illness are consistently described as risk factors for delirium. No effective prophylactic or curative treatments for postoperative delirium have been identified.

**Ketamine and delirium**

Ketamine is an anaesthetic agent that has been in common use for more than 50 years. It has a wide margin of safety, and as of 2005 had been studied in over 12 000 operative and diagnostic procedures, involving over 10 000 patients from 105 separate studies (ketamine package insert 2005). There is a pharmacological rationale for using ketamine as a preventative measure against postoperative delirium based on its N-methyl-D-aspartate (NMDA) antagonism. Normally, excitatory amino acids such as glutamate and aspartate act as agonists at NMDA receptors, and in the setting of surgery and inflammation, they might promote excitotoxic injury and apoptosis. As an NMDA antagonist, ketamine has the potential to protect against such neurological injury. Ketamine has also been posited to inhibit HCN1 receptors, which mediate the hyperpolarisation-activated cation current. Such inhibition is pertinent to delirium because HCN channels are important for regulating states of consciousness and are upregulated by inflammation. HCN receptors are also thought to play a critical role in neuropathic pain through inflammatory cascades.

On the basis of the pharmacological rationale for neuroprotection, a 58-patient randomised controlled trial was conducted to determine whether ketamine might prevent delirium after major cardiac surgery. There was a significant reduction in postoperative delirium from 31% to 3% with the administration of low-dose ketamine (0.5 mg/kg) on induction of anaesthesia. Although encouraging, this trial must be regarded as preliminary owing to its small sample size and single-centre design. Interestingly, the same investigators also found that ketamine was associated with improved cognition beyond the immediate postoperative period. Differences between the ketamine and placebo groups were evident in tests of non-verbal memory, verbal memory and executive function. The investigators found that C reactive protein, a non-specific inflammatory marker, was similar at baseline in the ketamine and placebo groups. On the first postoperative day, C reactive protein was elevated in both groups, but was significantly higher in the placebo group. The investigators hypothesised that the neuroprotective effect of ketamine might have been, in part, attributable to its anti-inflammatory actions. In support of the plausibility of this hypothesis, ketamine use in another cardiac surgical population was similarly shown to attenuate postoperative increases in inflammatory markers.

An intraoperative subanaesthetic dose of ketamine is appealing as a potential preventative intervention for delirium, since it is inexpensive and has an excellent safety profile. A number of questions remain to be answered regarding postoperative delirium. Despite the fact that delirium is a common and serious postoperative complication, intraoperative factors contributing to pathogenesis have not been rigorously investigated, and only a few small trials have been conducted that examine interventions to decrease its incidence. It is also currently unknown whether postoperative delirium is preventable, particularly in patients with underlying vulnerabilities. Importantly, ketamine in higher (anaesthetic) doses has become less popular over time owing to its side effects, including hallucinations and emergence reactions, especially in younger patients. To ensure treatment effectiveness, the preliminary results identifying subanaesthetic doses of ketamine as a useful preventative intervention for postoperative delirium should therefore be confirmed or refuted using a large-scale, pragmatic, randomised controlled trial design prior to routine adoption of low-dose ketamine for this purpose.

**Acute and persistent pain**

Similar to delirium, both acute and persistent pain are common postoperative complications, with a negative impact on patients’ lives. The Joint Commission has established the prevention of severe postoperative pain as a benchmark of quality, and adequate pain management is increasingly viewed as a fundamental human right. Unfortunately, this standard of care has not been attained to date; it has previously been estimated that about a third of patients suffer severe acute postsurgical pain following major procedures. Furthermore, patients who have acute postoperative pain are more likely to develop chronic pain, and the incidence of persistent postoperative pain following major surgeries remains between 5% and 30%. As an antagonist at NMDA and HCN1 receptors, ketamine has powerful analgesic properties. A systematic review showed that a
single subanaesthetic dose of intraoperative ketamine was associated with decreased visual analogue pain scores up to 48 h postoperatively. At 24 h postoperatively, ketamine was associated with an impressive 16 mg decrease in total morphine consumption. Furthermore, adverse effects such as hallucinations were rarely reported when low-dose ketamine was administered during general anaesthesia. Consistent with these findings, a Cochrane systematic review reported that subanaesthetic doses of perioperative ketamine were associated with decreased postoperative pain, decreased morphine consumption and decreased nausea and vomiting. Adverse effects were mild or absent. An updated systematic review, which included 70 small studies involving 4701 patients, recently confirmed that, in a dose-dependent manner, subanaesthetic intraoperative ketamine was consistently associated with decreased postoperative pain despite decreased opioid consumption. The more painful the surgical procedure, the greater was the analgesic benefit attributable to ketamine. In keeping with the decreased opioid consumption, postoperative nausea and vomiting were also less frequent in patients who received ketamine. However, patients who had been randomised to ketamine reported hallucinations and nightmares more frequently. While efficacy data, based on numerous small studies, strongly suggest that supplementary ketamine should be used to decrease pain and opioid usage postoperatively, most practitioners have not incorporated low-dose ketamine into their routine practice. Preliminary data gathered from five institutions (see below for details) involved in the Prevention of Delirium and Complications Associated with Surgical Treatments (PODCAST) trial suggest that despite their knowledge regarding the analgesic and opioid-sparing effects, practitioners do not administer low-dose ketamine for pain because of concern for complications such as delirium. Thus, effectiveness data regarding the relationship of ketamine, delirium and pain are needed.

Although numerous small efficacy studies have shown that ketamine decreases acute postoperative pain, its role in preventing persistent postoperative pain has not been rigorously explored. Many causal mechanisms that are thought to be implicated in persistent pain and a single intraoperative intervention might not be sufficient to decrease its occurrence. However, there have been encouraging findings about the potential of NMDA antagonists to decrease postoperative persistent pain. In the ENIGMA trial, patients were randomised to receive intraoperative oxygen with either nitrogen or nitrous oxide, which, like ketamine, is an NMDA antagonist. The investigators found that among those patients who received nitrous oxide, there was an absolute decrease in the percentage of patients who experience persistent pain (baseline incidence=15%) at 3 months postoperatively of 7% (95% CI 1.9% to 13.9%). A randomised study has examined the potential beneficial effect of intraoperative ketamine on persistent postoperative pain among patients undergoing total hip replacement. This trial found a reduction in the ketamine group from

Table 1 Incidence of delirium in major surgeries

<table>
<thead>
<tr>
<th>Surgery type</th>
<th>Study</th>
<th>Population</th>
<th>Delirium rate (%)</th>
<th>Detection method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unselected</td>
<td>Radtke et al</td>
<td>Recovery room after elective general anaesthesia</td>
<td>9.9</td>
<td>Nu-DESC</td>
</tr>
<tr>
<td>Surgical ICU</td>
<td>Pandharipande et al</td>
<td>Surgical ICU</td>
<td>73</td>
<td>CAM-ICU</td>
</tr>
<tr>
<td>Head and neck</td>
<td>Weed et al</td>
<td>Trauma ICU</td>
<td>67</td>
<td>Not stated</td>
</tr>
<tr>
<td>Cardiac</td>
<td>Kazmierski et al</td>
<td>Major head and neck</td>
<td>17</td>
<td>Not stated</td>
</tr>
<tr>
<td></td>
<td>Rudolph et al</td>
<td>Cardiac surgery with CPB</td>
<td>Age &lt;60: 16.3</td>
<td>DSM-IV</td>
</tr>
<tr>
<td></td>
<td>Saczynski et al</td>
<td>Patients &gt;60 undergoing elective or urgent cardiac surgery</td>
<td>Age ≥60: 24.7</td>
<td>CAM</td>
</tr>
<tr>
<td>Cardiac</td>
<td>Kazmierski et al</td>
<td>Patients &gt;60 undergoing elective coronary artery bypass grafting or valve replacement surgery</td>
<td>43</td>
<td>CAM</td>
</tr>
<tr>
<td>Vascular</td>
<td>Marcantonio et al, Schneider et al, Bohner et al, and Benoit et al</td>
<td>Abdominal aortic aneurysm repair</td>
<td>33–54</td>
<td>CAM or DSM-IV</td>
</tr>
<tr>
<td></td>
<td>Schneider et al and Bohner et al</td>
<td>Periperal vascular</td>
<td>30–48</td>
<td>DSM-IV</td>
</tr>
<tr>
<td></td>
<td>Fisher and Flowerdew</td>
<td>Patients &gt;60 undergoing elective orthopaedic procedures</td>
<td>17.5</td>
<td>CAM</td>
</tr>
<tr>
<td>Orthopaedic</td>
<td>Marcantonio et al and Lee et al</td>
<td>Patients &gt;65 undergoing emergent hip fracture repair</td>
<td>30.2–41</td>
<td>CAM</td>
</tr>
</tbody>
</table>

CAM, Confusion Assessment Method; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth edition; ICU, intensive care unit; Nu-DESC, The Nursing Delirium Screening Scale.

21% to 8% (reduction=13%; 95% CI 1.3% to 24.9%) in patients experiencing persistent pain at 6 months after their surgery. The PODCAST study would demonstrate whether a subanaesthetic dose of intraoperative ketamine is effective at preventing acute postoperative pain in a real-world setting. If ketamine was shown to have a substantial effect in decreasing acute postoperative pain, a next step would be to investigate rigorously its impact on persistent pain.

Current utilisation of low-dose ketamine

A survey of anaesthesia clinicians was conducted at five of the institutions (Washington University in St Louis, University of Michigan, University of Manitoba, Weill Medical College of Cornell University and Medical College of Wisconsin) participating in the PODCAST clinical trial. In total, 270 clinicians responded to the surveys; 18% (range among institutions 12–40%) of respondents currently incorporate adjunctive subanaesthetic ketamine into their practice. Interestingly, 84% of survey respondents believe that low-dose ketamine decreases acute postoperative pain, 81% feel that it decreases postoperative opioid consumption and 51% believe that it decreases chronic postoperative pain. However, the reason that a minority of practitioners are currently administering adjunctive ketamine is probably because many remain concerned about the neurological side effects of even low-dose ketamine; 68% of respondents expressed concern about hallucinations, 62% about delirium and 55% about nightmares.

Potential impact of PODCAST

The PODCAST trial has a novel focus in that it is assessing the impact of an intervention (subanaesthetic racemic ketamine administration) on delirium and pain, two adverse and potentially linked outcomes that have not previously been jointly evaluated in a single large clinical trial. Both delirium and pain are surprisingly common acute postoperative complications with major negative consequences for patients. Currently, there are no official guidelines to screen patients for delirium, and only a few preventive measures have been investigated, with disappointing results. Since most patients with postoperative delirium have a hypoactive phenotype, it is frequently missed in clinical practice. As noted previously, postoperative delirium is associated with increased intensive care and hospital stay, with persistent cognitive decline and with increased mortality. Thus, any intervention that could decrease the incidence of postoperative delirium would probably have major positive implications for older patients undergoing surgical procedures. Unlike delirium, acute postoperative pain is routinely assessed, and the Joint Commission has prioritised the prevention of severe postoperative pain as a universal goal. Unfortunately, this objective has not been met, and both severe acute pain and debilitating chronic pain continue to afflict many surgical patients. Of note, both pain and its treatment with opioid analgesics can be risk factors for delirium. Opioid analgesics are the mainstay therapy for postoperative pain, but their administration is curtailed in older patients particularly for safety considerations regarding respiratory depression, but also for concerns about causing sedation and delirium.

Pragmatic trials are intended to generate evidence of effectiveness of a test, treatment, procedure or healthcare service. At present, there is a lack of pragmatic trials for candidate interventions to prevent important and common postoperative neurological and psychiatric complications including delirium and pain. Ketamine is a plausible prophylactic option for each of these neurological and psychiatric complications. The American Society of Anesthesiologists has published Practice Guidelines for the management of acute and chronic pain, which, based on small efficacy or observational trials, include ketamine as a treatment option. There are currently no guidelines for the prevention of postoperative delirium. Thus, a multicentre pragmatic trial comparing low-dose ketamine with placebo is timely. It is important to emphasise that any one of several potential results of the PODCAST trial will have important and immediate positive implications for older surgical patients. First, ketamine might decrease both delirium and pain. This result would provide clear support for a larger comparative effectiveness trial testing ketamine as a prophylactic measure for both of these outcomes. Second, ketamine might decrease pain without increasing delirium. This result would provide compelling data that encourage the use of ketamine to prevent pain without concern for cognitive side effects such as delirium. Third, ketamine might decrease delirium and have no impact on pain. Although the lack of effect on pain is unlikely, this result would also encourage further study of the use of prophylactic intraoperative ketamine. However, low-dose ketamine may be found to increase delirium, regardless of its impact on pain. This result would suggest that the incorporation of intraoperative ketamine into routine clinical practice for older surgical patients is not warranted and would negate the need for a larger pragmatic trial. Furthermore, the PODCAST trial will help determine ketamine dose-related effects by comparing two doses (0.5 and 1 mg/kg) to placebo. As such, all of these potential results of the PODCAST trial have the potential to impact clinical practice and will be generalisable to all older surgical patients undergoing major surgical procedures because of the permissive inclusion criteria and the simplicity of intervention.

METHODS AND ANALYSIS

Study design

PODCAST is a prospective randomised controlled trial that has been designed in accordance with the CONSORT guidelines and will evaluate whether a
single bolus dose of racemic ketamine (0.5 or 1 mg/kg) following induction of anaesthesia and before surgical incision decreases the incidence or severity of postoperative delirium and pain in a mixed elderly (>60 years) surgical patient population. Patients will undergo the standard preoperative anaesthesia assessment. Follow-up information will be collected from the medical chart for up to 5 years. The overall study design is outlined in figure 1.

Eligibility criteria
Patients 60 years old and older, who are competent to provide informed consent and who are undergoing major open cardiac surgery (eg, coronary artery bypass graft, valve replacement) or non-cardiac surgeries (eg, thoracic surgery, major vascular surgery, intra-abdominal surgery, open gynaecological surgery, open urological surgery, major orthopaedic surgery, hepatobiliary surgery and major ENT surgery) and receiving general anaesthesia, will be eligible for inclusion. The exclusion criteria are based on the contraindications to ketamine from the 2005 ketamine package insert. Patients with an allergy to ketamine and those in whom a significant elevation of blood pressure would constitute a serious hazard (eg, pheochromocytoma, aortic dissection) will be excluded. We shall also exclude patients with drug misuse history (eg, ketamine, cocaine, heroin, amphetamine, methamphetamine, 3,4-methylenedioxyn-N-methylamphetamine (MDMA), phencyclidine, lysergic acid, mescaline, psilocybin), patients taking antipsychotic medications (eg, chlorpromazine, clozapine, olanzapine, risperidone, haloperidol, quetiapine, paliperidone, amisulpride, sertindole) and patients with a weight outside the range 50–200 kg (110–440 lbs). Patients will be enrolled either during a preoperative clinic visit or in the hospital prior to surgery.

Baseline assessment
At the time of enrolment, patients will undergo the same delirium and pain evaluation that will be used postoperatively (see Outcomes section). Additionally, patients will be screened for functional dependence using the Barthel Index of Activities of Daily Living, 47 for depression using the Patient Health Questionnaire (PHQ-8) 48 and for obstructive sleep apnoea using the STOP-Bang criteria. 49 Patients will be asked if they have a history of delirium, and if this presented after surgery. They will also be asked about any falls they have experienced in the 6 months prior to surgery. Comorbid conditions, including the components of the Charlson Comorbidity Index, 50 will be obtained by reviewing the patients’ medical records. Any available preoperative laboratory results, including electrolytes and blood counts, will also be recorded.

Interventions
As this is a pragmatic trial, apart from administration of the study drug (ketamine or normal saline), all decisions about anaesthetic technique will be made by the anaesthetic team assigned to each patient. The only exception is that clinicians will be instructed not to administer any ketamine other than the study drug. The intention of this trial is to interfere as little as possible with the usual process of care, which will increase the applicability of the findings. 43 Following the induction of general anaesthesia, an intravenous dose of 0.5 mg/kg racemic ketamine, 1 mg/kg racemic ketamine or an equivalent volume of normal saline will be injected via a reliable (free-flowing) central or peripheral intravenous line. Clinicians will be blinded to the treatment arm of the study. Anaesthetic factors such as the use of nitrous oxide, protocols for pain prevention, use of neuraxial anaesthesia, use of nerve blocks and other practices that could potentially affect primary or secondary outcomes will be assessed in a post hoc manner.

Outcomes
Primary outcomes
Trained members of the research team who are blinded to the treatment arm of the study will assess patients for delirium (primary outcome) using the Confusion Assessment Method (CAM) 51 and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) 52, 53 for patients who are unable to speak (eg, have a tracheal tube or tracheostomy) on the ICU. These methods (the CAM and the CAM-ICU) have been shown to be reliable and to have good agreement with the DSM-IV criteria for delirium. 54–55 Delirium assessment will be performed when patients can be aroused sufficiently in order to be assessed for delirium (Richmond Agitation and Sedation Score ≥4). The first delirium assessment will be attempted if feasible on the day of surgery in the afternoon/evening. Patients will then be assessed for delirium twice daily (from postoperative day 1 to postoperative day 3) in the morning and in the afternoon/evening with at least 6 h between assessments. Each patient will be assessed for delirium up to seven times. At the Washington University site, the patients’ family members will perform the Family Confusion Assessment Method (FAM-CAM) separately from the investigators performing their assessments. 56 Investigators and family members will be blinded to each other’s assessments. The FAM-CAM has demonstrated high sensitivity and specificity for detection of delirium and good agreement with the CAM, 56 but has not been specifically evaluated in the postoperative setting. After the final delirium assessment, patients will complete the Delirium and Pain Self-Assessment Questionnaire (see online supplementary appendix A). Incident delirium subsequent to this period is unlikely to be directly related to anaesthetic or other intraoperative factors.

Secondary outcomes
Study team members blinded to the treatment group of the patient will assess all secondary outcomes. Acute pain (secondary outcome) will be assessed prior to surgery...
and then postoperatively by using the Behavioral Pain Scale (BPS)\textsuperscript{57} or the Behavioral Pain Scale for the Non-Intubated patient (BPS-NI)\textsuperscript{58} and the 10 cm VAS (Visual Analog Scale) at the same times as patients are assessed for delirium. The BPS-NI has been shown to be a valid and reliable tool for measuring pain in a predominantly delirious patient population.\textsuperscript{58} Interviewers will rate the BPS or BPS-NI prior to asking the patient to complete the VAS to prevent bias in the BPS and BPS-NI assessments. The postoperative daily amount of opioids and sedatives administered will be ascertained from the patient’s electronic health record spanning the period after surgery until the final delirium assessment is complete. After the final delirium assessment, patients will complete the Delirium and Pain Self-Assessment Questionnaire (see online supplementary appendix A). Postoperative nausea and vomiting (secondary outcome) will be assessed at the same time points that patients are
assessed for delirium by asking patients to rate the severity of their nausea and vomiting, if present, on a three-point scale (mild, moderate, severe). Patients will be questioned at each assessment about side effects, especially hallucinations and nightmares. Intensive care unit and hospital length of stay will be obtained from the patient’s medical record. At some of the participating sites in the PODCAST trial, patients will receive a survey, which will be sent by mail or email 1 month following surgery. This survey will collect patient-reported outcomes on depressive symptoms, affect, persistent pain, functionality and quality of life. Depressive symptoms will be assessed with the eight-item PHQ-8. Affect will be assessed with two 10-item mood scales that comprise the Positive and Negative Affect Schedule (PANAS) within 3–6 months postoperatively. The same screens for depressive symptoms and affect will also be conducted in the hospital on postoperative day 3. Persistent pain will be assessed with the Brief Pain Inventory Short Form (BPI-SF). The Barthel Index will be used to report functionality, and quality of life will be assessed from the Veteran’s Rand-12 (VR-12) questionnaire.

Standardisation of training and outcomes assessment
All study team members who perform delirium assessments will undergo a rigorous training process. For the initial training, representatives from each study site participated in a full-day training programme led by SKI, the original creator of the CAM. Those who attended this initial training will oversee the training of other team members at their sites. Trainees must demonstrate competence at both conducting CAM interviews and in scoring these interviews. For the initial part of training, trainees must conduct at least two satisfactory CAM interviews in the presence of a trained team member. These interviews will not be on patients enrolled in the PODCAST trial. To establish their ability to score CAM interviews reliably, trainees will accompany trained team members to conduct CAM interviews. A trained member of the research team will conduct each CAM interview for patients enrolled in the PODCAST trial. The trainee will observe the interview, but will score the CAM independently. The trainee must agree with the trainer on the presence or absence of all 12 cognitive features assessed by the CAM on a minimum of two delirious and two non-delirious patients. After meeting the stipulations of training, the newly trained team member will conduct their first interview of a patient enrolled into the PODCAST trial in the presence of a previously trained team member.

Assessment of the standardisation and reliability of delirium assessments
After training, all PODCAST team members administering delirium assessments will be invited to participate in a project to demonstrate the validity and reliability of the CAM in our study population. Participants will view and rate eight videos of standard interviews depicting delirious and non-delirious patients. They will also independently score the CAM for each scenario. Demographic information, level of education, level of clinical experience and primary language will also be collected from all participants. Data will be de-identified. All scores and data will be submitted to the lead site, Washington University. The group’s scores will then be compared to determine the reliability of delirium assessments across sites. Additionally, the group’s scores will be compared with a set of ‘gold standard’ scores for the videos (determined by SKI’s team). This comparison is intended to demonstrate the validity of the CAM in our study setting. Overall, the goal of the project is to demonstrate standardisation of the delirium outcome across all study sites.

Sample size
On the basis of the published delirium incidences in the scientific literature (table 1), we estimate conservatively that the incidence of postoperative delirium in a mixed major surgical population of older patients will be between 20% and 25%. Based on data from a sub-study of the BAG-RECALL trial that we have recently completed, the incidence of delirium among patients admitted to our cardiothoracic intensive care unit at Barnes-Jewish Hospital is 25% within three postoperative days. Hudetz et al27 found that ketamine was associated with a 28% (95% CI 8% to 46%) absolute risk reduction in delirium (from a baseline incidence of 31%). A 28% reduction is likely to be an overoptimistic effect size for designing a pragmatic study; 10% is more realistic as the most optimistic effect size and remains consistent with the CI for the effect size found by Hudetz et al27. Assuming a two-sided type I error rate of 5%, a sample size of 600 will give greater than 80% power to detect a decrease in the incidence of delirium from 25% to 15% with ketamine. On the other hand, we consider the minimum clinically important difference (MCID) or effect size to be 2%, which corresponds to a number needed to treat 50 surgical patients to prevent one episode of delirium. The rationale for the low MCID is that delirium is a serious postoperative complication that is associated with increased mortality and the proposed intervention (low-dose ketamine) is safe, inexpensive and not likely to have adverse effects.

There are two specific issues to clarify in this study: (1) the likely effect size with ketamine and (2) the optimal ketamine dose. Ketamine might increase delirium, decrease delirium or have no impact on delirium. If ketamine increases delirium, it might be more likely to increase delirium at a higher dose (1 mg/kg). If ketamine decreases delirium, it might have a dose–response effect:—less delirium at the higher ketamine dose (1 mg/kg). We anticipate that ketamine will decrease pain in a dose-dependent manner—1 mg/kg will be superior to 0.5 mg/kg. Accrual of 200 patients to each dose of ketamine along with a placebo arm will allow a more robust assessment of the dose–response efficacy for postoperative analgesia than previous studies with
fewer numbers. In general, the higher ketamine dose might have more side effects. As such, this trial might inform whether the higher ketamine dose can be used, in view of its possibly superior analgesia, with a potential benefit in relation to delirium and without excessive side effects. The dosage determination going forward will depend on the observed incidence of delirium with each dose, analgesia efficacy with each dose and side effect profile with each dose. The proposed design for the study is shown in table 2.

With this approach, we believe that this study will clearly inform whether it is indicated, both in terms of efficacy as well as feasibility, to pursue a larger study. The purpose of the larger study (PODCAST2) will be to determine definitively whether ketamine is associated with a reduction in delirium (and pain) in high-risk older surgical patients, without incurring an increase in side effects. As the main effect evaluated will be to determine whether ketamine decreases delirium, table 3 provides a useful guide for the potential findings of the current study with their implications.

**Recruitment**

This clinical trial will be conducted at Washington University in St Louis and other sites. Our research team has conducted large randomised controlled trials, which enrolled (approximately) 2000 patients over 14 months in the B-unaware trial,60 6000 patients over 26 months in the BAG-RECALL trial60 and 22 000 patients over 24 months in the Michigan Awareness Control Study.61 On the basis of the inclusion criteria and the number of eligible surgical patients, we estimate that 1 year will be sufficient for patient enrolment to the proposed trial, and a further 1 year for data analysis.

**Allocation**

Participants will be block randomised by the hospital pharmacy departments in groups of 15 (1:1:1 ratio—0.5 mg/kg ketamine; 1 mg/kg ketamine: placebo), stratified by site, in order to keep the randomisation balanced and the groups more homogeneous. The outcome of this random assignment will be concealed from the study team, and all study participants and trial staff will be blinded to the randomisation. Codes will be held by the hospital pharmacies and they will dispense medication. Randomisation codes will remain concealed until the primary analysis is completed. Prepared syringes of either placebo or ketamine will be directly delivered to the operating room in which surgery of the consenting patient will take place as soon as the research team informs the pharmacy about the patient going to the operating room for surgery.

**Data analysis and management**

Data analysis for this investigation will require comparisons of patient outcomes (eg, delirium, pain, length of stay, adverse events) in the three study groups to assess significant differences among ketamine doses (placebo, 0.5 mg/kg and 1 mg/kg). For proportions and categorical outcomes, such as incident delirium, we will use the $\chi^2$ test (or Fisher’s exact test in the case of sparse data) to compare proportions across the three groups and the Cochran-Armitage test to test for dose-response trends. For continuous outcomes, such as visual analogue pain scores and opioid consumption, we will use repeated-measures analysis of variance tests to detect the main effects. The Tukey post hoc test will also be run on all significant interactions to determine differences between individual and combined groups (eg, placebo vs combined ketamine groups; 0.5 vs 1 mg/kg ketamine). For multivariate analyses, we will apply the Cox proportional hazards model for recurrent events to investigate the effects of low doses of intraoperative ketamine on delirium by comparing its occurrence and timing across the study groups. We will also model the number of postoperative delirium incidents using a Poisson hurdle regression to find out the difference in the proportion of patients with and without delirium, and for those who experience delirium, the difference in its recurrence. Both models (Cox proportional hazards and hurdle model) will account for differences in ketamine effectiveness in cardiac versus non-cardiac surgery by including interaction terms for ketamine dose and cardiac surgery status, while adjusting for other influential variables. We will also use mixed-effects regression models to assess differences among subgroups in continuous outcome variables over time (eg, postoperative pain scores and opioid consumption). These models will likewise account for interactions between ketamine dose and cardiac surgery status. All statistical testing will be two-sided, and $p$ values $<$0.05 will be regarded as significant. No interim analyses are planned. Appropriate adjustment will be made for multiple analyses.

The Division of Biostatistics Informatics Core at Washington University will be used as a central location for data processing and management. Washington University belongs to a consortium of institutional partners that works to maintain a software toolset and workflow methodology for electronic collection and management of research and clinical trial data. REDCap (Research Electronic Data Capture) data collection projects rely on a thorough study-specific data dictionary defined in an iterative self-documenting process by all members of the research team with planning assistance from the Division of Biostatistics Informatics Core. The iterative development and testing process results in a

<table>
<thead>
<tr>
<th><strong>Table 2</strong> Patient allocation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group</strong></td>
</tr>
<tr>
<td>Placebo</td>
</tr>
<tr>
<td>Ketamine low dose (0.5 mg/kg)</td>
</tr>
<tr>
<td>Ketamine moderate dose (1 mg/kg)</td>
</tr>
</tbody>
</table>
well-planned data collection strategy for individual studies. REDCap servers are securely housed in an on-site limited access data centre managed by the Division of Biostatistics at Washington University. All web-based information transmission is encrypted. The data are all stored on a private firewall protected network. All users are given individual user IDs and passwords and their access is restricted on a role-specific basis. REDCap was developed specifically around HIPAA-Security guidelines and is implemented and maintained according to the Washington University guidelines. REDCap currently supports >500 academic/non-profit consortium partners on six continents and 38 800 research end users.62

### Monitoring

The research team will monitor the study for adverse events. All serious adverse events will be reported to the Institutional Review Board (IRB) according to the IRB stipulations. The monitoring plan for this study is appropriate for the planned pragmatic trial. As an anaesthetic drug, ketamine has an excellent safety profile and record. In particular, low-dose ketamine (0.5 or 1 mg/kg) administered prior to surgical incision is unlikely to be associated with major adverse events, and even minor side effects manifesting after induction of anaesthesia and the start of surgery are improbable.63

The PODCAST trial will have an appropriate data and safety monitoring plan for a low-risk clinical trial. There will be a charter to guide the functions of the Data Safety and Monitoring Board (DSMB), and the DSMB will produce reports in accordance with the NIH guidelines. The DSMB will provide independent oversight of the PODCAST trial and will review the general conduct of the trial as well as study data for participant safety.64

The DSMB will comprise independent, multidisciplinary experts who will make recommendations regarding the continuation, modification or termination of the trial.65 The members will have the requisite expertise to examine accumulating data, to protect the integrity of the clinical experiments in which the patients have consented to participate and to assure the regulatory bodies and the public (and possibly funding agencies) that conflicts of interest do not compromise either patient safety or trial integrity.66 There will be no prespecified interim analysis given the size of this study; frequent analyses might increase the likelihood of bias.64 There will be a provision for early stoppage for safety concerns, but not for efficacy or for futility.64 Trials that stop early for benefit show implausibly large treatment effects, particularly when the number of events is small.67 Truncated trials have been associated with greater effect sizes than trials not stopped early, independent of the presence of statistical stopping rules.68

All members of the DSMB will be at the Washington University site. Local investigators at all participating sites will report serious adverse events, or unanticipated problems involving risks to participants or others, to their IRB and to the principal investigator (PI) of the study at Washington University. If such problems are considered to be related to the trial, then they will also be reported to IRBs at other participating sites and to the chairperson of the DSMB. The members of the DSMB will have no direct involvement in the conduct of the PODCAST trial. Neither will they have financial, proprietary or professional conflicts of interest, which may affect the impartial, independent decision-making responsibilities of the DSMB.64 65 Letters of invitation to prospective DSMB members will include the following: “Acceptance of this invitation to serve on the PODCAST DSMB confirms that I do not have any financial or other interest with any of the collaborating or competing pharmaceutical firms or other organizations involved in the study that constitute a potential conflict of interest.”69

---

### Table 3 Potential findings of PODCAST

<table>
<thead>
<tr>
<th>Delirium incidence in placebo groups (N=200) (%)</th>
<th>Delirium incidence in ketamine groups (N=400) (%)</th>
<th>Effect size (reduction in delirium with ketamine) (%)</th>
<th>95% CI for effect size (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 (N=50)</td>
<td>25 (N=100)</td>
<td>0</td>
<td>-7.6 to 7.1</td>
</tr>
<tr>
<td>Implication: consider pursuing a larger study only if pain is decreased in ketamine groups, and there is no increase in side effects</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25 (N=50)</td>
<td>22.5 (N=90)</td>
<td>2.5</td>
<td>-4.5 to 10.0</td>
</tr>
<tr>
<td>Implication: although the point estimate is &gt;2% (MCID), a 9500 patient study would be required to clarify more precisely the effectiveness of ketamine in preventing delirium. Other outcomes in the study (eg, pain reduction and side effects) would inform the approach</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25 (N=50)</td>
<td>20 (N=80)</td>
<td>5</td>
<td>-1.9 to 12.4</td>
</tr>
<tr>
<td>Implication: pursue a larger study with approximately 2500 patients to clarify more precisely the effect of ketamine on preventing delirium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25 (N=50)</td>
<td>17.5 (N=70)</td>
<td>7.5</td>
<td>0.7 to 14.8</td>
</tr>
<tr>
<td>Implication: pursue a larger study (approximately 1200 patients) to clarify whether effect size &gt;2% (MCID) and to define it more precisely</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>15</td>
<td>10</td>
<td>3.3 to 17.1</td>
</tr>
<tr>
<td>Implication: for a main effect, a lower bound of CI &gt;2% (MCID). Ketamine’s benefit in decreasing delirium is very likely, but a larger study (approximately 1200 patients) would define its effect more precisely</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PODCAST, Prevention of Delirium and Complications Associated with Surgical Treatments; MCID, minimum clinically important difference.
All DSMB members will sign a Conflict of Interest Certification to confirm that no conflict exists. There will be between three and eight people on the DSMB, in order to optimise performance.69 The DSMB will be advisory rather than executive on the basis that it is the PODCAST trial investigators who are ultimately responsible for the conduct of the trial.69

The risks associated with this study are low. There is a rare risk of breach of confidentiality. In contrast to other anaesthetics, protective reflexes such as coughing and swallowing are maintained with low-dose ketamine. The 2005 package insert for ketamine reports the induction dose for anaesthesia as follows: the initial dose of ketamine administered intravenously may range from 1 to 4.5 mg/kg. The average amount required to produce 5–10 min of surgical anaesthesia has been 2 mg/kg. The short-term side effects of ketamine at higher doses (≥1–2 mg/kg) than the dosages proposed for this study (0.5 or 1 mg/kg) include tachycardia, nystagmus, hypersalivation, euphoria, emergence reactions, hallucinations and nightmares.70 It is possible, but very unlikely, that low-dose ketamine (0.5 or 1 mg/kg) administered just after induction of anaesthesia or administration of sedative medications will cause these side effects.37 38 63 Emergence reactions, hallucinations and nightmares are more common in younger patients receiving ketamine. In published studies on low-dose ketamine (0.25–1 mg/kg) administered during general anaesthesia, side effects have generally not been found.37 The main side effects that might occur are nightmares and hallucinations. Other neuropsychiatric side effects might occur, most likely within the first 24 h after surgery, and will be determined from patient interviews. The incidence of these side effects in this patient population is currently unknown, and thus side effects will be reported separately and jointly. Meta-analysis suggests that ketamine might be associated with an increase in neurological and psychiatric side effects from approximately 5% to 7.5%. This study will be >80% powered to detect an increase in side effects from 5% to 12% and 20% powered to detect an increase in side effects from approximately 5% to 7.5%. As part of the informed consent process for this study, patients will be informed of the rare risks and will be asked about them after their surgery. In the unlikely event that serious side effects occur, they will be documented and also reported to the human research protection office and to the study’s DSMB. Participants will not incur any study-related expenses, and nor will they be financially compensated for their participation.

Ethics and dissemination
Ethics approval and consent
The PODCAST trial has been approved by the IRBs of the PI’s home institutions (Washington University, St Louis and University of Michigan, Ann Arbor). IRB approval has also been obtained at some of the participating sites (Postgraduate Institute of Medical Education and Research, Chandigarh, India; University of Manitoba, Winnipeg, Canada; Weill Medical College, Cornell University, New York City; Medical College of Wisconsin, Milwaukee) and is ongoing at other sites. Recruitment began in February 2014 and will continue until the end of 2016. Potential participants will be approached for enrolment by a member of the research team who will explain the purpose of the study and written informed consent will be obtained for all participants. Patients may choose not to participate in this study and there will be no penalty in terms of the care that they receive.

Confidentiality
Necessary protected health information will only be shared with members of the research team. To help protect confidentiality, research charts will be stored in a locked cabinet inside the locked research office. Electronic data and demographic information will also be kept in a password-protected electronic database stored on the departmental network drive and only accessible via password-protected departmental computers. A member of the research team will enter this information. Code numbers, rather than names, will appear on any data and documents used for evaluation or statistical analyses.

Dissemination
Dissemination plans include presentations at local, national and international scientific conferences. There are no publication restrictions and no professional writers will be involved in the generation of the manuscript.

CONCLUSIONS
In the next four decades, the US population over the age of 60 is predicted to double to more than 80 million individuals. The ageing population often requires surgery, which can be frequently complicated by post-operative pain and delirium. Delirium is defined as an acute brain dysfunction that presents as fluctuating levels of inattention and disordered thinking, and has been reported to affect up to 70% of surgical patients older than 60. Likewise, severe postoperative pain continues to affect a large proportion of surgical patients, especially the elderly, and is another major contributor to delirium. Unfortunately, opioid medications, the current standard for analgesia, can themselves lead to delirium and other adverse consequences. Clinicians therefore face the paradox that both pain and the mainstay treatment of pain can lead to delirium. Although causal relationships have not been established, postoperative delirium is associated with increased ICU and hospital stay, persistent cognitive decline and increased mortality rate. What is needed is a therapeutic intervention that can both attenuate pain and decrease the occurrence of delirium. Mounting evidence suggests that the intraoperative administration of low-dose (ie, subanaesthetic) ketamine, an anaesthetic drug that has been in common use for 50 years, prevents delirium,
lessens the severity of postoperative pain, and has an opioid-sparing effect. These multiple beneficial effects have been attributed to ketamine’s anti-inflammatory and antiexcitotoxic actions. Despite these benefits, low-dose intraoperative ketamine currently does not enjoy widespread adoption, primarily because clinicians are concerned that the psychoactive properties of ketamine might compromise postoperative cognition. The PODCAST randomised controlled trial intends to address a gap in the field through an international multicentre study that tests the effectiveness of ketamine in reducing both delirium and pain in surgical patients older than 60.

Author affiliations
1Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri, USA
2Department of Anesthesiology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
3Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
4Clement J. Zablocki VA Medical Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
5Department of Anesthesiology, Asan Medical Center, Seoul, South Korea
6Department of Anesthesiology, Weil Cornell Medical College, New York, New York, USA
7Department of Anesthesiology, University of Bern, Bern, Switzerland
8Department of Anesthesiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
9Department of Anesthesiology, Virginia Mason Medical Center, Seattle, Washington, USA
10Department of Anesthesiology, University of Manitoba-Faculty of Medicine, Winnipeg, Manitoba, Canada
11Department of Anesthesiology, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada
12Department of Surgery, Thoracic, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
13Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Hebrew SeniorLife, Boston, Massachusetts, USA
14Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan, USA

Acknowledgements

Collaborators
SW Ku; BM Choi; IC Choi; J Bang; E Rogers; SD Gandhi; R Downey; Z Iqbal; KM Patterson; ME Davis; H Yulico; S Oskar; J Aveek; A Villarfranca; R Arora; J McGavch; L Girling; M Engoren; M Malle; A Alexander; J Neal; N Hanson; D Emmert; T Wildes; M Bottros; E Lenze; B Tellor; A Cai.

Contributors
MSA and GAM are the primary authors of the PODCAST protocol. Their contributions include drafting and editing the protocol, conceptualising the study design, and organising conduct across all sites. BAF contributed to the PODCAST trial by editing the protocol, conceptualising the study design, creating the electronic database REDCap used for data collection and coauthoring a manual of operations for study conduct. HRM contributed to the PODCAST trial by editing the protocol, conceptualising the study design, creating the electronic database REDCap used for data collection and coauthoring a manual of operations for study conduct. KEE contributed to the PODCAST trial by editing the protocol, conceptualising the study design, and outlining conduct across all sites. MRM contributed to the PODCAST trial by editing the protocol, conceptualising the study design, recruiting patients for enrolment and coordinating the study across all sites. Their contributions include drafting and editing the protocol, and conceptualising the study design. YC contributed to the PODCAST trial by editing the protocol and conceptualising the study design. ABA contributed to the PODCAST trial by editing the protocol and conceptualising the study design, including the statistical modelling of the study. SKI contributed to the PODCAST trial by training investigators to perform delirium assessments and conceptualising the study design. SC, RJD, HPG, GN, JAH, EJ, HK, PSP, KP, RP, RAV and VKA contributed to the PODCAST trial by editing the study protocol, conceptualising the study design, recruiting participants and collecting data. All authors including MSA, GAM, BAF, HRM, MRM, KEE, YC, ABA, SKI, RAV, HPG, JAH, KP, PSP, VKA, RF, EJ, HPG, HK, RJD and SC have critically revised the PODCAST protocol and approved the final version. All authors agree to be accountable for the accuracy and integrity of all aspects of the PODCAST trial.

Competing interests
None.

Ethics approval
The Washington University in St. Louis Institutional Review Board.

Provenance and peer review
Not commissioned; externally peer reviewed.

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES